Usefulness of 64Cu-ATSM in head and neck cancer: A preliminary prospective study

Clinical Nuclear Medicine

Volumn 39, Issue 1, 2014, Pages

  Grassi, Ilaria ^a   Nanni, Cristina ^a   Cicoria, Gianfranco ^a   Blasi, Claudio ^a   Bunkheila, Feisal ^a   Lopci, Egesta ^a   Colletti, Patrick M ^b   Rubello, Domenico ^c   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

18F FDG PET CT; 64Cu ATSM PET CT; Biologic tumor volume (BTV); Head and neck cancer; Hypoxia; Radiotherapy treatment planning

Indexed keywords

CETUXIMAB; CISPLATIN; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ACUTE TOXICITY; ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EARLY DIAGNOSIS; FEMALE; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; IMAGE ANALYSIS; LARYNX CANCER; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NASOPHARYNX CANCER; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; SENSITIVITY AND SPECIFICITY; TONSIL CANCER; TREATMENT PLANNING; TREATMENT RESPONSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK TUMOR; MULTIMODAL IMAGING; PATHOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; SCINTISCANNING; TUMOR VOLUME;

FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; THIOSEMICARBAZONES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84891560874     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182a756f0     Document Type: Article

References (29)

1. Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013;25:229-234
2. Bauman J, Langer C, Quon H, et al. Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. Exp Ther Med. 2013;5:1247-1253
3. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9: 539-549
4. Dehdashti F, Gribsby PW, Mintum MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic responseVa preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238
5. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30: 844-850
6. Dietz DW, Dehdasthti F, Gribsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60 Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: A pilot study. Dis Colon Rectum. 2008;51:1641-1648
7. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study. Ann Nucl Med. 2011;25:339-345
8. Lewis JS, Laforest R, Dehdashti F, et al. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008; 49:1177-1182
9. Lewis JS, Laforest R, Buettner T, et al. Copper-64-diacetyl-bis(N4 methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98: 1206-1211
10. Fujibayashi Y, Taniuchi H, Yonecura Y, et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160
11. Dearling JL, Lewis JS, Mullen GE, et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-Activity relationships. J Biol Inorg Chem. 2002;7:249-259
12. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548-1555
13. Cashman EC, MacMahon PJ, Shelly M, et al. Role of positron emission tomographyYcomputed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593-602
14. Obata A, Kasamatsu S, McCarthy DW, et al. Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron. Nucl Med Biol. 2003;30:535-539
15. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of nocarrier-Added 2-[18F]-fluoro-2-deoxy D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238
16. Suzuki O, Nishiyama K, Morimoto M, et al. Defining PET standardized uptake value threshold for tumor delineation with metastatic lymph nodes in head and neck cancer. Jpn J Clin Oncol. 2012;42:491-497
17. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). 2010 I.C.R.U. Report 83. 2010;10:1-106
18. Pignon JP, le Maître A, Maillard E, et al. Meta-Analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14
19. Bernier J, Schneider D. Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer. 2007;43:35-45
20. Yue J, Yang Y, Cabrera AR, et al. Measuring tumor hypoxia with 18F-FETNIM PET in esophageal squamous cell carcinoma: A pilot clinical study. Dis Esophagus. 2012;25:54-61
21. Zimmer LA, Snyderman CH, Fukui MB, et al. The use of combined PET/CT for localizing recurrent head and neck cancer: The Pittsburgh experience. Ear Nose Throat J. 2005;84:104-110
22. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: A novel paradigm for radiation therapy prescription. Semin Radiat Oncol. 2011;21:101-110
23. Korreman SS, Ulrich S, Bowen S, et al. Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta Oncol. 2010;49: 964-971
24. Dalah E, Bradley D, Nisbet A. Simulation of tissue activity curves of (64)Cu-ATSM for sub-Target volume delineation in radiotherapy. Phys Med Biol. 2010; 55:681-694
25. Grègoire V, Chiti A. Molecular imaging in radiotherapy planning for head and neck tumors. J Nucl Med. 2011;52:331-334
26. Newbold K, Powell C. PET/CT in radiotherapy planning for head and neck cancer. Front Oncol. 2012;2:189
27. Buck AK, Schirrmeister H, Mattfeldt T, et al. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging. 2004;31: S80YS87
28. Dandekar P, PartridgeM, Kazi R, et al. Challenges in integrating 18FDG PET-CT into radiotherapy planning of head and neck cancer. Indian J Cancer. 2010;47: 260-266
29. Dierckx RA, Van der Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging. 2008;35:1544-1549